DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension

Inclusion Criteria: 1. Male or female patient aged between 50 to 75 years old (both included); 2. Patient with mild to moderate essential hypertension at enrollment, which defined as the following: Patient must have mean sitting SBP ≥140 and \<180 mmHg or mean sitting DBP ≥90 and \<110 mmHg at enrollment; 3. Patient with normal serum potassium; 4. Patient or his/her legally acceptance representative has signed the written informed consent form. Exclusion Criteria: 1. Patient with severe hypertension (mean sitting DBP ≥ 110 mmHg or mean sitting SBP ≥ 180 mmHg); 2. Patient with secondary hypertension, such as coarctation of aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc; 3. Patient is under treatment with beta-blocker prior to enrollment; 4. A definite diagnosis or unstable of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, arrhythmia and heart failure within 3 months before signing the written informed consent form; 5. Patient with concomitant endocrine diseases or type 1 Diabetes Mellitus; 6. Patient with type 2 Diabetes Mellitus with poor glucose control (glycosylated hemoglobin \> 9% or fasting blood sugar \> 250 mg/dL at enrollment) or under insulin treatment; 7. Patient with clinically unstable disease such as known collagen or auto-immune disease or other malignant disease requiring current medication; 8. Patient with bilateral renal artery stenosis, solitary kidney or post renal transplant; 9. Patient with clinically relevant hematological disease; 10. Hepatic or renal dysfunction as defined by the following parameters: * ALT or AST \> 2 times upper limit of normal, * Total bilirubin \> 2 times upper limit of normal, * Serum creatinine \>2.0 mg/dl; 11. Female patient who is pregnant or lactating; 12. Patient with substance abuse (including alcohol) history for the past two years; 13. Known or suspected contraindications, including allergy to DMTA07 or calcium channel blockers; 14. Patient received other investigational drug or device within 30 days before signing the written informed consent form; 15. Patient with any other serious disease considered by the investigator(s) not in the condition to enter the trial.